Literature DB >> 3207463

Footprinting studies on the interactions of nogalamycin, arugomycin, decilorubicin and viriplanin with DNA.

K R Fox1.   

Abstract

DNase I footprinting studies employing several DNA fragments have confirmed that nogalamycin binds preferentially to regions of DNA containing alternating purines and pyrimidines. Arugomycin and viriplanin A, related compounds which contain additional sugar residues at both ends of the molecule, produce similar patterns of nuclease protection though at higher drug concentrations. The pattern induced by decilorubicin, which has charged groups at both ends of the aglycone, differs in many details and this analogue appears to display a modified DNA sequence selectivity. The results have been confirmed by similar studies using DNase II. All four compounds increase the susceptibility of certain adenine residues to modification by diethylpyrocarbonate. The results suggest an intercalative mode of binding for these nogalamycin analogues, and reveals an increased complexity in compounds which can bind to DNA by this mechanism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3207463

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  4 in total

1.  Anthracycline antibiotic arugomycin binds in both grooves of the DNA helix simultaneously: an NMR and molecular modelling study.

Authors:  M S Searle; W Bicknell; L P Wakelin; W A Denny
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

2.  Structure of nogalamycin bound to a DNA hexamer.

Authors:  L D Williams; M Egli; G Qi; P Bash; G A van der Marel; J H van Boom; A Rich; C A Frederick
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

3.  High resolution hydroxyl radical footprinting of the binding of mithramycin and related antibiotics to DNA.

Authors:  B M Cons; K R Fox
Journal:  Nucleic Acids Res       Date:  1989-07-25       Impact factor: 16.971

4.  'SPKK' motifs prefer to bind to DNA at A/T-rich sites.

Authors:  M E Churchill; M Suzuki
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.